Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 16;29(3):593–604. doi: 10.1038/s41591-022-02189-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 3 — a-c, Comparison of the percentage of viable tumor in resected tumor specimens with: known EGFR mutant/ALK rearranged (n = 11) and EGFR wt/ALK wt (n = 20), median percentage of viable tumor: EGFR mutant/ALK rearranged 45% (range 0.6 – 94%), EGFR wt/ALK wt 45.8 (range 0 – 95.5%) (a); known KRAS mutant (n = 9) and KRAS wt (n = 22), median percentage of viable tumor: KRAS mutant 31.2% (range 0 – 94.5%), KRAS wt 50.5% (range 0 – 95.5%) (b); known TP53 altered (n = 15) and TP53 wt (n = 16), median percentage of viable tumor: TP53 altered 29.4% (range 0 – 90%), TP53 wt 61.4% (range 1.3 – 95.5%) (c). d-f, Percentage of viable tumor in resected tumor specimens with: known EGFR mutant/ALK rearranged tumors (Nivo+CT, n = 5; Ipi+Nivo+CT, n = 6), median percentage of viable tumor in Nivo+CT 39.5% (range 16.3 – 90%), in Ipi+Nivo+CT 51.5% (range 0.6 – 94%) (d); known KRAS mutant (Nivo+CT, n = 4; Ipi+Nivo+CT, n = 5), median percentage of viable tumor in Nivo+CT 73.3% (range 2.5 – 94.5%), in Ipi+Nivo+CT 4.4% (range 0 – 41.7%) (e); known TP53 altered (Nivo+CT, n = 9; Ipi+Nivo+CT, n = 6), median percentage of viable tumor in Nivo+CT 39.5% (range 0 – 90%), in Ipi+Nivo+CT 15.5% (range 0 – 57.9%) (f). Tumor alterations are shown as amino acid change; the splice site variants c.673-1 G>T and c.673-2A>T are shown as codon change. One patient (who had tumor TP53 alteration) was not included due to death from SARS-CoV-2 infection-related complications (non-treatment related) during neoadjuvant treatment. Dashed line at 10% point depicts cutoff for MPR. The green filled and empty circles depict data from MPR and no MPR, respectively, in Nivo+CT patients; the red filled and empty circles depict data from MPR and no MPR, respectively, in Ipi+Nivo+CT patients. Data are presented as median with minima, lower and upper quartiles, and maxima using violin plots. The dashed line indicates the median; the dotted lines indicate the lower quartile and upper quartile values; top and bottom indicate the maxima and minima. MPR, major pathologic response; Nivo, nivolumab; Ipi, ipilimumab; CT, chemotherapy; wt, wild type.